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Abstract 
Background Atrial fibrillation (AF) is the most common sustained arrhythmia, with growing 
evidence identifying obesity as an important risk factor for the development of AF. Although 
defective atrial myocyte excitability due to stress-induced remodeling of ion channels is 
commonly observed in the setting of AF, little is known about the mechanistic link between 
obesity and AF. Recent studies have identified increased cardiac late sodium current (INa,L) 
downstream of calmodulin-dependent kinase II (CaMKII) activation as an important driver of 
AF susceptibility. 
Methods Here, we investigated a possible role for CaMKII-dependent INa,L in obesity-induced 
AF using wild-type (WT) and whole-body knock-in mice that ablates phosphorylation of the 
Nav1.5 sodium channel and prevents augmentation of the late sodium current (S571A; SA mice). 
Results A high-fat diet (HFD) increased susceptibility to arrhythmias in WT mice, while SA 
mice were protected from this effect. Unexpectedly, SA mice had improved glucose homeostasis 
and decreased body weight compared to WT mice. However, SA mice also had reduced food 
consumption compared to WT mice. Controlling for food consumption through pair feeding of 
WT and SA mice abrogated differences in weight gain and AF inducibility, but not atrial 
fibrosis, premature atrial contractions or metabolic capacity. 
Conclusions These data demonstrate a novel role for CaMKII-dependent regulation of Nav1.5 in 






Atrial fibrillation (AF) affects ~3 million people in the USA alone [1] with an expected 
incidence of 15 million by 2050 [2]. AF is highly correlated with multiple risk factors including 
heart failure, age, obesity, and type 2diabetes (https://www.cdc.gov/obesity/adult/causes.html) 
[3–5]. Among these, the growing incidence in obesity (https://www.who.int/en/news-room/fact-
sheets/detail/obesity-and-overweight) has been identified as a major risk factor for AF [1,6,7] 
and is implicated in 17.9% of all AF cases [7]. Although the incidence of AF and obesity is 
rapidly increasing worldwide, the causative link between the two pathologies is not clear. 
It is well-established that atrial excitability undergoes dramatic changes in the setting of 
AF, which further exacerbates the substrate for atrial arrhythmia (atrial remodeling). Studies 
have shown that defects in atrial myocyte Ca2+ handling are important in atrial remodeling, 
leading to aberrant membrane excitability and dysregulation of critical Ca2+-dependent signaling 
pathways [8,9]. Previous work from our group and others showed that calmodulin protein kinase 
II (CaMKII) dependent regulation of voltage-gated sodium channels (Nav) is a critical 
determinant of AF susceptibility in animal and humans [10–16]. Specifically, CaMKII 
phosphorylates the alpha subunit of cardiac Nav (Nav1.5) at Ser571 in the DI-DII linker, leading 
to increased pathogenic late current (INa,L), which promotes arrhythmogenic action potential after 
depolarizations and further disrupts intracellular Ca2+ handling [8–10,15]. This increase in INa,L 
has been observed in animal models and patients with AF, and drugs that target INa,L have shown 
promise as therapeutic targets for AF. Importantly, whole-body knock-in mice lacking the 
Ser571 site in Nav1.5 (SA mice) have reduced AF inducibility [8]. 
Obesity increases pericardial fat mass, induces left atrial remodeling, and is a major risk 
factor for AF[17–21]. Although INa,L has been recognized as an important driver of AF, the 
impact of obesity on INa,L has not been studied. Here, we investigated whether diet-induced 
obesity increased susceptibility to AF in wild-type (WT) mice, and whether the SA knock-in 
mouse model had reduced susceptibility to AF, even in the presence of a high-fat diet. Similar to 
previous studies [22,23], we found that diet-induced obesity increased AF susceptibility 
compared to age-matched, chow-fed WT mice. Ablation of CaMKII-dependent phosphorylation 
of Nav1.5 was protective against the development of AF under conditions of diet-induced 
obesity. Surprisingly, we also found that the SA allele improved glucose metabolism, and 
reduced body weight gain associated with HFD, likely due to decreased food intake. Mitigating 
the difference in food intake by pair-feeding WT mice to SA mice reduced atrial arrhythmia 
events in WT mice, but the improvements in glucose metabolism were still maintained. Taken 
together, these data highlight the novel role of Nav1.5 in mediating susceptibility to AF and 




Male, 18–24-week-old C57BL/6 mice from Jackson Laboratory (WT mice) orScn5aknock-in 
mice with a Ser-to-Ala mutation at Ser571 of the cardiac voltage-gated channel Nav1.5 (SA 
mice) were used for all experiments[10]. Animals were housed at room temperature (22 °C) on a 
12-h light/dark cycle. All procedures were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals published by the National Institutes of Health following 
protocols approved by the IACUC at The Ohio State University. Animals were euthanized using 
isoflurane and cervical dislocation followed by collection of tissue or cell isolation. 
 
High-fat diet and pair feeding 
WT and SA mice were fed a chow (20% kcal from fat; Teklad) or high-fat diet (60% kcal from 
fat; Research Diets Inc.) for 6 or 12 weeks. WT and SA mice were fed ad libitum throughout the 
study unless otherwise indicated. In a subset of experiments, pair-feeding of WT and SA mice 
was performed by measuring daily food intake of SA mice and calculating the difference in food 
consumption from the previous day. Each WT mouse was randomly paired to a specific SA 
mouse and fed the calculated food consumption for that SA mouse each day for 6 weeks. 
Atrial arrhythmia susceptibility 
To measure susceptibility to atrial arrhythmia events in vivo, subsurface ECGs were obtained 
from anesthetized mice using subcutaneous ECG leads in the lead II configuration and recording 
software (Powerlab, ADInstruments).Mice were anesthetized using 2% isoflurane with an 
oxygen flow rate of 1.0 L/min, and then placed in laying position on a heating pad to maintain 
body temperature. 1.5% isoflurane was used to maintain anesthesia. Recordings were taken at 
baseline for 3 min, with epinephrine (1.5 mg/kg, intraperitoneal) for 3 min, and with caffeine 
(120 mg/kg, intraperitoneal) for 10 min. LabChart (ADInstruments) was used to analyze the data 
for premature atrial contractions (PACs) in the 10 min following epi/caffeine injection (PACs/10 
min),as well as for the severity of atrial tachycardia or fibrillation(AT/AF). AT was defined as at 
least three premature p-waves in rapid succession (i.e., three premature p-waves within 100 ms), 
while AF was defined as a period of R–R variability without discernible p-waves. The AT/AF 
score was assigned based on the duration of AT/AF during the10 min following epi/caffeine 
injection, with a score of 0 corresponding to no incidence of AT/AF, a score of 1 to<1 s of 
AT/AF, a score of 2 to 1–10 s of AT/AF, a score of 3to 10–60 s of AT/AF, and a score of 4 to >1 
min of AT/AF.A subset of WT mice fed a high-fat diet was injected with mexiletine (25 mg/kg) 
or saline 15 min before baseline ECG recording began. 
Echocardiography 
To assess left atrial remodeling, echocardiographic images were obtained from anesthetized mice 
following 6 weeks of HFD. Mice were anesthetized using 2% isoflurane, and1.5% isoflurane was 
used to maintain anesthesia. Left atrial diameter was measured along the parasternal long axis 
view using a Vevo2100 (VisualSonics) system with the MS-400transducer. 
Histology and imaging 
Left atria were fixed in neutral buffered 10% formalin, processed routinely into paraffin, and 
then sectioned serially at 5 μm. Sections were stained using Masson’s Trichrome to examine the 
amount of interstitial and perivascular fibrosis, wheat germ agglutinin Alexa488 Conjugate to 
evaluate cell cross-sectional area, and TUNEL kits to examine the amount of apoptosis. Fibrosis 
was quantified using a custom-built MATLAB program [24]. Cell cross-sectional area was 
evaluated using ImageJ. 
Body composition and metabolic testing 
Body weight was measured using an OHAUS NV212 scale. Body fat and lean mass were 
measured using an EchoMRI instrument (EchoMRI LLC) with canola oil calibration 
[25].Glucose tolerance testing was performed after a 12-h fast with drinking water available ad 
libitum. Blood glucose was assessed at baseline by a tail vein prick. Glucose was administered 
by intraperitoneal injection (2 g glucose/kg body weight or per kg lean mass) at 0 min, and the 
tail vein prick was used to measure blood glucose levels at 15, 30, 60, and 120 min post injection 
[25]. Insulin tolerance testing was performed following a 2 h fast with drinking water ad lib. 
Baseline blood glucose levels were measured using a tail vein prick. Insulin was administered by 
intraperitoneal injection (1 unit per kg body weight) at 0 min. Blood glucose levels were 
measured at 10, 15, 30, 45, and 60 min post injection. If at any time a mouse dropped below40 
mg/dL glucose, they were given an intraperitoneal injection of 200μL of 20% glucose (0.1 g/mL) 
and subsequently removed from the test. Pyruvate tolerance testing was performed after a 12-h 
fast with drinking water available ad libitum. Baseline blood glucose levels were measured using 
a tail vein prick. Pyruvate was administered intraperitoneally (2 g sodium pyruvate/kg body 
weight) at0 min and blood glucose levels were measured 15, 30, 45, 60, and 90 min post 
injection [26]. 
Comprehensive lab animal monitoring system 
The Comprehensive Lab Animal Monitoring System (Oxymax Opto-M3; Columbus 
Instruments) was used to measure activity level, volume of O2 consumption, volume of 
CO2production, and heat production. Total energy expenditure of mice was calculated as 
described previously [27]. Data were collected over 48 h; 24 h in the fed state and24 h in the 
fasted state. 
Quantitative PCR 
Tissue processing and quantitative PCR (qPCR) were per-formed as previously described [28]. 
Sigma-Aldrich custom primers were used for genes of interest with the sequences shown in 
Supplementary Table 1. All qPCR gene expression was normalized to the housekeeping gene 
GAPDH. 
Western blotting 
Tissue processing and immunoblotting were performed as previously described [26]. The 
GAPDH (Fitzgerald; 10R-G109A), phosphorylated CaMKII at Thr286/287 (pCaMKII) (Thermo 
Fisher; MA1-047), and CaMKII (Badrilla; A010-56AP) antibodies were commercially sourced, 
and phosphorylated Nav1.5 at Ser571 (p Nav1.5) and Nav1.5 antibodies were custom generated, 
as described previously [10,15]. All immunoblotting data were normalized to GAPDH. 
Statistical analysis 
GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. 
The sample sizes in each experiment are provided in figure legends. Only ill and/or wounded 
animals were excluded from the analyses (n=2inthis study). The data are presented as means ± 
SEM. Statistical significance was defined as P< 0.05 and determined by two-tailed t-test or one-
or two-way ANOVA, with Tukey and Bonferroni post hoc analysis. 
 
Results 
SA mice are resistant to weight gain and atrial arrhythmias induced by high-fat diet 
To investigate the role of diet-induced obesity on susceptibility to AF, WT and SA mice 
were fed a high-fat diet for 6 weeks (WT-HFD and SA-HFD, respectively). SA-HFD mice had 
reduced total body weight and body weight gain compared to WT-HFD mice (Fig.1A, B). 
To determine the effects of HFD on susceptibility to atrial arrhythmia, WT-HFD mice, 
age-matched chow-fed WT (WT Chow) mice, and SA-HFD mice underwent adrenergic 
challenge using epi/caffeine, and changes in the incidence of atrial arrhythmia events [PACs and 
atrial tachycardia/fibrillation (AT/AF)] were measured. WT-HFD mice had increased incidence 
and severity of PACs and AT/AF compared to WT Chow mice (Fig.1C–E). Interestingly, SA-
HFD mice were resistant to the HFD-induced increase in atrial arrhythmia events (Fig.1C–
E).Similar to their response on a chow diet [8], SA mice had little to no PACs or AT/AF events 
even after 6 weeks of ahigh-fat diet. Consistent with a role for CaMKII-dependent 
phosphorylation of Nav1.5 in atrial arrhythmia, elevated levels of phosphorylated/activated 
CaMKII (pCaMKII) and phosphorylated Nav1.5 at S571 (p Nav1.5) were observed in whole 
heart lysates from WT-HFD compared to WT Chow without any difference in total Nav1.5 (Sup. 
Figure 1A). Interestingly, SA-HFD hearts were resistant to the increase in pCaMKII observed in 
WT-HFD (Supplementary Fig. 1B) (p Nav1.5 was not evaluated in SA-HFD due to the loss of 
antibody epitope as previously reported [10]). Overall, these data indicate that preventing 
CaMKII-dependent phosphorylation of Nav1.5 confers resistance to body weight gain and 
reduces susceptibility to AF under conditions of diet-induced obesity. 
Inhibition of the late sodium current with Mexiletine reduces susceptibility to arrhythmias 
Given that increased INa,L leads to atrial arrhythmias in high-fat fed mice, we assessed the 
effect of the Na+ channel blocker mexiletine on arrhythmia susceptibility in WT-HFD mice [8]. 
Consistent with the hypothesis that increased INa,L downstream of CaMKII-dependent 
phosphorylation of Nav1.5 increases susceptibility to obesity-induced AF, treatment with 
mexiletine eliminated PACs and AT/AF in WT-HFD mice (Fig.2A–C). These data provide the 
first evidence that dysregulation of voltage-gated sodium channels contributes to HFD-induced 
AF. 
SA mice are resistant to HFD-induced cardiac remodeling 
Previous studies have shown that obesity or a high-fat diet contribute to atrial remodeling 
and susceptibility to arrhythmias [17,19,21]. To investigate whether phospho-ablation of Nav1.5 
protects against HFD-induced atrial remodeling, atrial size and structure were analyzed by 
echocardiography and immunohistochemistry. Echocardiography data revealed that HFD 
increased atrial chamber size in WT-HFD, but not SA-HFD mice. In fact, SA-HFD mice and WT 
Chow mice had similar atrial chamber size (Fig.3A, B). HFD also increased atrial myocyte 
cross-sectional area in WT, but not SA mice (Fig.3C, D). These data indicate that HFD induces 
pathological atrial hypertrophy in WT mice, while SA mice are resistant to this adverse 
remodeling. 
In addition to pathological remodeling, AF is associated with increased apoptosis and 
tissue fibrosis. To determine if a high-fat diet affected atrial myocyte apoptosis and fibrosis, 
TUNEL staining was performed in WT Chow, WT-HFD, and SA-HFD mice. WT-HFD mice 
had increased apoptosis (Fig.3E, F) and fibrosis (Fig.3G, H) compared to WT Chow mice. 
Moreover, SA mice were resistant to the HFD-induced increase in apoptosis and fibrosis 
(Fig.3E–H).These data indicate that phosphorylation of Nav1.5 is an important contributor to the 
development of HFD-induced atrial apoptosis and fibrosis. Together, these data demonstrate that 
phospho-ablation of the Nav1.5 channel negates HFD-induced atrial remodeling and arrhythmias. 
SA mice have improved metabolic capacity 
SA mice are protected from HFD-induced arrhythmias and atrial remodeling 
(Figs.1and3). It is important to note that these findings are confounded by significant differences 
in body weight between the WT-HFD and SA-HFD mice (Fig.1), which are also present in WT 
and SA chow-fed mice(Supplementary Fig. 2A). This difference is likely due to altered food 
consumption as SA mice consumed significantly less food compared to WT mice on a chow 
diet(Supplementary Fig. 2B). Glucose tolerance was improved in SA chow-fed mice compared 
to WT chow-fed mice when injected with glucose based on either body weight (Supplementary 
Fig. 2C, D) or lean mass (Supplementary Fig.2E, F). There was no difference in insulin tolerance 
or pyruvate tolerance between SA and WT mice on a chow diet (Supplementary Fig. 2G–J). 
These data indicate that attenuation of INa,L can affect metabolic capacity even on a chow diet. 
SA-HFD mice were protected from diet-induced obesity and AF. Since metabolic 
dysfunction is a co-morbidity for obesity and AF, we investigated the effects of a high-fat diet on 
the metabolic health of SA mice. After 6 weeks of ahigh-fat diet, SA mice (SA-HFD) had a 
preserved glucose tolerance when injected with glucose based on body weight (Fig.4A, B) or 
lean mass (Supplementary Fig. 3A, B),preserved insulin tolerance (Fig.4C, D), and pyruvate 
tolerance (Fig.4E, F) compared to high-fat fed wild-type mice(WT-HFD). SA-HFD mice had 
reduced fat mass and lean mass after 6 weeks of HFD compared to WT-HFD 
mice(Supplementary Fig. 3C–F). We measured metabolic capacity after 12 weeks of a high-fat 
diet via indirect calorimetry and determined that SA mice had increasedVO2, VCO2, and 
respiratory exchange ratio (RER) (Fig.4G–I), indicating that these mice predominantly used 
carbohydrates as a fuel source. These data indicate that pre-venting CaMKII-dependent 
phosphorylation of Nav1.5 leads to improved metabolic health in addition to having a protective 
effect on atrial remodeling and reduced susceptibility to arrhythmia. 
Since the SA mice are a whole-body knock-in mouse, we investigated gene expression 
changes in several tissues to determine a potential role in mediating whole-body metabolic 
health. Expression of genes involved in mitochondrial metabolism, fatty acid oxidation, and 
glucose metabolism were measured in the liver, tibialis anterior (TA) skeletal muscle, 
interscapular brown adipose tissue (iBAT), inguinal subcutaneous white adipose tissue 
(ingWAT), and the small intestine. These tissues were selected for their documented roles in 
metabolism, and specifically glucose metabolism [25,29,30]. The small intestine was 
investigated because it expresses Nav1.5 in rodents and humans [31–33]. Select genes related to 
mitochondrial metabolism and fatty acid oxidation were increased in the liver, TA, iBAT, 
ingWAT, and small intestine of SA-HFD mice compared to WT-HFD mice (Supplementary Fig. 
4A–O). Interestingly, there were no changes in expression of genes involved in glucose 
metabolism in any of the tissues measured (Supplementary Fig. 4A–O). These data indicate that 
some genes involved in mitochondrial and fatty acid metabolism are altered in multiple 
peripheral tissues in the SA mice and may con-tribute to whole-body changes in metabolism. 
Differences in body weight account for improved AT/AF susceptibility, but not metabolism in 
SA-HFD mice 
SA-HFD mice have reduced susceptibility to arrhythmias and improved metabolic health 
compared to WT-HFD mice. It is important to note that these findings are con-founded by 
significant differences in body weight (Fig.1A,B). Similar to a chow-fed mice, SA mice had 
reduced food intake compared to WT mice on HFD (Supplementary Fig.2B, Fig.5A). To 
determine if the differences in food intake were the primary driver for the difference in body 
weight, resistance to arrhythmia development, and improved metabolic health in SA-HFD mice, 
we investigated a separate cohort of mice where food intake in WT-HFD mice was paired to that 
of SA-HFD mice (WT-HFD-PF) (Supplementary Fig. 5A). Pair-feeding blunted the HFD-
induced weight gain observed in ad libitum fed WT mice (Fig.5B,C; Supplementary Fig. 5B, C). 
Pair-feeding also abolished the differences in fat mass (Supplementary Fig. 5D), percent fat mass 
(Fig.5D), and percent lean mass (Fig.5E), but not total lean mass (Supplementary Fig. 5E), 
between WT-HFD and SA-HFD mice. In parallel, pair-feeding reduced the difference in fibrosis 
between the both groups compared to WT-HFD, although a significant increase in fibrosis was 
still apparent in WT-HFD-PF compared to SA-HFD (Supplementary Fig. 5F, G). 
To determine if susceptibility to AT/AF was primarily in response to changes in body 
weight, WT-HFD-PF mice were compared toad libitum fed WT-HFD mice, WT Chow mice 
(Fig.1C, D), and SA-HFD mice. While pair-feeding did not eliminate differences in PACs 
between WT-HFD-PF and SA-HFD mice (Fig.5F), pair-feeding reduced incidence of AT/AF in 
WT-HFD-PF mice (Fig.5G). WT-HFD-PF mice had a lower AT/AF score compared to WT-
HFD mice (Figs.1D and5G), with no significant differ-ences in AT/AF score between WT-HFD-
PF, WT Chow, or SA-HFD mice (Figs.1D and5G). These data indicate that the SA allele reduces 
severity of atrial arrhythmia events dependent on food consumption and weight gain. 
To determine if the observed metabolic improvements were dependent on body weight in 
SA-HFD mice, we investigated the metabolic health of WT-HFD-PF mice compared to SA-HFD 
mice. To account for the slight differences in body weight, mice were injected with glucose 
based on lean mass and glucose tolerance was measured. Even when injected based on lean 
mass, glucose tolerance was improved in SA-HFD compared to WT-HFD-PF mice (Fig.6A, B). 
Insulin tolerance was not different between groups (Supplementary Fig. 5H, I), but pyruvate 
tolerance was improved in SA-HFD mice, indicating that SA-HFD mice had improved 
gluconeogenic activity compared to WT-HFD-PF mice (Fig.6C, D). Together these data indicate 
that the effects of improved glucose and pyruvate tolerance were not dependent on body weight. 
Indirect calorimetry measurements revealed that SA-HFD mice had increased VO2 and 
VCO2compared to WT-HFD-PF mice, but with no difference in RER (Fig.6E–G). Interestingly, 
WT-HFD-PF mice had increased RER compared to ad libitum WT-HFD mice (Fig.6H), 
indicating a shift to increased carbohydrate utilization in these mice, similar to SA-HFD mice. 
Taken together, these data indicate that SA-HFD mice have systemic improvements in metabolic 
health compared to WT-HFD-PF mice that are independent of body weight. 
 
Discussion 
In this study, we investigated the link between CaMKII-dependent regulation of Nav1.5, 
pathogenic late current(INa,L), diet-induced obesity, and AF, taking advantage of our phospho-
ablated SA knock-in mouse model lacking the CaMKII phosphorylation site on Nav1.5, which 
attenuates INa,L. Diet-induced obesity resulted in increased arrhythmias and obesity-induced atrial 
remodeling (fibrosis, pathological hypertrophy, apoptosis) in WT mice, but phospho-ablation of 
Nav1.5 in the SA knock-in mice conferred resistance to obesity-induced arrhythmias and atrial 
remodeling. More-over, phospho-ablation of Nav1.5 resulted in improved metabolic capacity in 
mice, independent of body weight. This highlights a novel role for the late Na+ current to 
modulate whole-body metabolism. 
Dysregulation of Nav1.5 is frequently reported in animal models of AF and human 
patients [8,34–37]. Our group and others have demonstrated that dysregulation of Nav1.5 
mediates atrial arrhythmogenesis downstream of CaMKII activation [8,10,12]. Of specific 
interest, previous work has shown that in addition to other targets involved in AF pathogenesis, 
CaMKII phosphorylates Nav1.5 at Ser571 in both atrial and ventricular myocytes, directly 
augmenting INa,L and disrupting intracellular homeostasis of both Na+ and Ca2+[8,10,38]. 
Dysregulation of Nav1.5 Ser571 has been observed in multiple cardiac disease states, including 
heart failure, ischemia/reperfusion, and AF [38–40]. In addition, drugs like ranolazine that target 
INa,L have been successfully employed to treat AF [34,41,42]. However, the role of INa,L in stress-
induced AF, such as that resulting from aging, heart failure, and obesity, remains unclear. An 
outstanding question to be answered going forward is how does a high-fat diet promotes 
CaMKII/Nav1.5 dysregulation and atrial structural/electrical remodeling to set the stage for 
increased susceptibility to atrial arrhythmias? Previous work has shown increased CaMKII 
activity with a high-fat diet downstream of increased oxidative stress [43]. At the same time, 
accumulation of epicardial adipose tissue has been linked to atrial remodeling through paracrine 
signaling [44,45]. Thus it is likely that changes in the volume/com-position of fat depots adjacent 
to the atria may drive the remodeling process and arrhythmia, although further investigation is 
needed. 
Here, we determined that HFD increased atrial arrhythmia burden in WT mice, but 
preventing augmentation of INa,L in SA reduced susceptibility to the development of arrhythmias. 
Surprisingly, SA mice also had an improved metabolic profile compared to WT-HFD mice, 
independent of their body weight. These improvements were similar to previous studies 
investigating the role of the INa,L inhibitor ranolazine. The HARMONY and RAFFAELLO trials 
have shown that ranolazine decreases AF burden and recurrence in AF patients [46,47]. In 
addition, pre-clinical and clinical studies have reported that ranolazine induces weight loss and 
improves glycemia in patients with type 2 diabetes and coronary heart disease [48–50]. Although 
the mechanism remains unclear, it has been proposed that ranolazine may alter metabolism by 
reducing glucagon release from the pancreas, or by modulating fatty acid uptake, oxidation, and 
gluconeogenesis in the liver [51–53]. Based on our findings, it is possible that metabolic benefits 
of Nav1.5 phospho-ablation and ranolazine are mediated through similar mechanisms. 
While Nav1.5 is predominantly expressed in the heart, Nav1.5 is also found in other 
tissues [54,55]. The impact of Nav1.5 on glucose metabolism in tissues other than the heart has 
not been studied. Since the SA mouse model is a whole-body knock-in model, effects on 
peripherally expressed Nav1.5 could mediate the observed metabolic benefits. Analysis of genes 
in the liver, TA, iBAT, ingWAT, and small intestine indicates some changes to mitochondrial 
and glucose metabolism in SA-HFD mice that warrant further studies to better determine their 
role in improving metabolic capacity. 
It is important to note that SA mice had lower food intake on HFD compared to WT mice 
which reduced the weight gain in these animals. Attenuating body weight gain by pair-feeding 
WT and SA mice eliminated differences in HFD-induced AT/AF but not PACs in WT mice 
compared to SA mice. This indicates that reduced body weight gain likely reduces the severity of 
the AF disease state, but not arrhythmogenic triggers factors like PACs. In contrast, improved 
glucose metabolism was still observed in SA-HFD mice compared to WT-HFD-PF, suggesting a 
direct effect of Nav1.5 on metabolism. Future studies should investigate the impact of therapeutic 
treatments such as ranolazine on food intake in patients, as well as mechanisms behind decreased 
food intake and its role in metabolic effects of Nav1.5. Moreover, it will be of value to highlight 
the relative importance of modulating cardiac-specific changes in Nav1.5 activity, relative to 
extra-cardiac Nav1.5. Interestingly, the use of mexiletine successfully reduced AF burden in WT-
HFD mice with just 15 min of pre-treatment, suggesting a critical importance of direct 
electrophysiologic action of Ser571 in acutely contributing to AF burden. It will be interesting to 
see how this differs from the chronic contributions of Ser571 to the structural changes of atrial 
hypertrophy and fibrosis and how such changes incorporate extra-cardiac Nav1.5. It is also worth 
noting that cardiac-specific transgenic models have altered systemic energy homeostasis, 
suggesting that modulation of cardiac Nav1.5 alone may be sufficient to induce non-cardiac 
changes in metabolic regulation and energy storage [56]. 
Overall, these data demonstrate a previously under-studied interaction between the 
CaMKII/Nav1.5 pathway, AF, and obesity. Phospho-ablation of the Nav1.5 site, Ser571, that 
regulates INa,L reduces AF susceptibility by attenuating weight gain and improves whole-body 
glucose metabolism independent of body weight. Together, these data establish Nav1.5 as an 
important driver for whole-body metabolic health and reiterate its importance in arrhythmic 
susceptibility under conditions of diet-induced obesity. These data also highlight the need to 
better elucidate the mechanistic basis for observed changes to metabolism and arrhythmia 
susceptibility with future studies. This study provides greater understanding of the interplay 
between co-morbidities like cardiovascular diseases, obesity, type 2 diabetes and their 
underlying effectors. Analysis of the mechanistic aspects of these diseases, especially the role of 
the late Na+ current in this context, can further the under-standing and treatment of these co-
morbidities in humans. 
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Fig. 1: SA knock-in allele confers resistance to body weight gain and reduces susceptibility 
to atrial fibrillation on a high-fat diet. (A) Body weight of WT-HFD and SA-HFD mice after 6 
weeks of HFD; (B) changes in body weight for WT-HFD and SA-HFD mice after 6 weeks of 
HFD. Data are presented as means ± SEM (WT-HFD n = 27, SA-HFD n = 13; *p < 0.05, 
****p < 0.0001 vs WT-HFD). (C) Density of pre-atrial contractions; (D) severity of AT/AF 
based on a score of 0 (none) to 4 (severe); and E representative ECGs following injection of 
epinephrine (1.5 mg/kg) and caffeine (120 mg/kg). Data are presented as means ± SEM (WT 
Chow n = 22, WT-HFD n = 23, SA-HFD n = 14; *p < 0.05, **p < 0.01, ***p < 0.001 vs WT-
HFD). 
 
Fig. 2: Inhibition of INa,L with Mexiletine reduces susceptibility to atrial fibrillation under 
conditions of diet-induced obesity. (A) Density of pre-atrial contractions; (B) severity of 
AT/AF based on a score of 0 (none) to 4 (severe) following injection of epinephrine (1.5 mg/kg) 
and caffeine (120 mg/kg); and (C) representative EKGs from 6-week high-fat diet mice injected 
with saline or mexiletine followed by exposure to epinephrine/caffeine. Data are presented as 
means ± SEM (WT-HFD n = 23, WT + HFD + Mex n = 8) (*p < 0.05 vs WT-HFD). 
 
Fig. 3: SA knock-in mouse model is resistant to high-fat diet-induced cardiac remodeling. 
(A) Representative echocardiograms (Scale bar 1 mm) and (B) quantification of left atrial 
diameters. Data are presented as means ± SEM (WT Chow n = 15, WT-HFD n = 15, SA-HFD 
n = 4; ***p < 0.001, ****p < 0.0001 vs WT-HFD). (C) Left atrial section cell membranes stained 
with Wheat germ agglutinin (Scale bar 10 μm) and (D) Cross-sectional areas measured from 
atrial cells to determine cell areas changes. Data are presented as means ± SEM (n = 3/group; 
*p < 0.05, **p < 0.01 vs WT-HFD). (E) TUNEL staining of left atrial sections to determine 
apoptosis (hot spots = nuclei with DNA fragmentation due to apoptosis; Arrows = toward hot 
spots; DAPI stain = location of all nuclei) (Scale bar 20 μm) and (F) Percentage of cells 
undergoing apoptosis. Data are presented as means ± SEM (WT Chow n = 4, WT-HFD n = 4; 
SA-HFD n = 3; *p < 0.05, **p < 0.01 vs WT-HFD). (G) Masson’s Trichrome staining of Left 
atrial sections to indicate fibrosis levels relative to normal cardiac tissue (Scale bar 200 μm) and 
(H) percentage of fibrotic tissue. Data are presented as means ± SEM (WT Chow n = 6, WT-HFD 
n = 6; SA-HFD n = 4; *p < 0.05 vs WT-HFD). 
 
Fig. 4: SA knock-in mouse model has improved metabolic capacity under conditions of 
diet-induced obesity. (A) Glucose tolerance test excursion curve and (B) glucose tolerance test 
area under curve after 6 weeks of HFD. Data are presented as means ± SEM (n = 5/group; 
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs WT-HFD). (C) Insulin tolerance test excursion 
curve and (D) insulin tolerance test area under curve after 6 weeks of HFD. Data are presented as 
means ± SEM (n = 5/group; **p < 0.01, ***p < 0.001, ****p < 0.0001 vs WT-HFD). (E) 
Pyruvate tolerance test excursion curve and (F) pyruvate tolerance test area under curve after 6 
weeks of HFD. Data are presented as means ± SEM (WT-HFD n = 5, SA-HFD n = 9; *p < 0.05, 
**p < 0.01, ****p < 0.0001 vs WT-HFD). (G) Volume of O2 consumption (H) volume of CO2 
production, and (I) respiratory exchange ratio of mice was measured and calculated using 
CLAMS monitoring system as described previously after 12 weeks of HFD [27]. Data are 
presented as means ± SEM (WT-HFD n = 5, SA-HFD n = 4; *p < 0.05, **p < 0.01 vs WT-HFD). 
 
Fig. 5: Attenuating body weight gain on HFD partially mitigates susceptibility to AF in 
wild-type mice compared to SA knock-in mice. (A) Average daily food intake of WT-HFD 
and SA-HFD mice on a high-fat diet. Data are presented as means ± SEM (WT-HFD n = 15, SA-
HFD n = 5; ****p < 0.0001 vs WT-HFD). Wild-type mice were pair-fed (WT-HFD-PF) the same 
amount of HFD as SA-HFD mice for 6 weeks and (B) body weight (C) changes in body weight 
measured. (D) changes in percent fat and (E) lean mass measured using EchoMRI. Data are 
presented as means ± SEM (WT-HFD-PF n = 9, SA-HFD n = 10). (F) Density of pre-atrial 
contractions and (G) severity of AT/AF based on a score of 0 (none) to 4 (severe) measured 
following injection of epinephrine (1.5 mg/kg) and caffeine (120 mg/kg). Data are presented as 
means ± SEM (WT-HFD-PF n = 7, SA-HFD n = 14; **p < 0.01 vs WT-HFD-PF). 
 
Fig. 6: Attenuating body weight gain on HFD does not affect metabolic capacity of wild-
type mice compared to SA knock-in mice. (A) Glucose tolerance test excursion curve and (B) 
area under curve for glucose tolerance after 6 weeks of pair-feeding. (C) Pyruvate tolerance 
excursion curve and (D) area under curve for pyruvate tolerance after 6 weeks of pair-feeding. 
Data are presented as means ± SEM (WT-HFD-PF n = 9, SA-HFD n = 10; *p < 0.05, **p < 0.01, 
****p < 0.0001 vs WT-HFD-PF). (E) Volume of O2 consumption; (F) volume of CO2 
production; (G, H) respiratory exchange ratio of mice measured using CLAMS Monitoring 
system after 6 weeks of pair feeding [27]. Data are presented as means ± SEM WT-HFD n = 5, 
WT-HFD-PF n = 9, SA-HFD n = 10; *p < 0.05, **p < 0.01 vs WT-HFD-PF (E–G) and vs WT-
HFD (H). 
 
Supplementary Figure 1. Six weeks of high-fat diet upregulates CaMKII and Nav1.5 
phosphorylation in WT-HFD mice. Representative immunoblots and densitometry showing 
(A) phosphorylated Nav1.5 at S571 (pNav1.5) relative to total Nav1.5 and (B) phosphorylated 
CaMKII at T286/287 (pCaMKII) relative to total CaMKII after 6 weeks of HFD. Data 
represented as means ± SEM(WT-chow n=4, WT-HFD n=9, SA-HFD n=4; *p<0.05 vs WT-
HFD) 
 
Supplementary Figure 2. SA mice have reduced weight, food intake and improved glucose 
tolerance compared to WT mice on a chow diet. (A) Body weight of WT and SA mice on a 
chow diet. Data are presented as means ± SEM (WT Chow n=22, SA-chow n=11; ****p<0.0001 
vs WT chow). (B) Average daily food intake of WT and SA mice on a chow diet. Data are 
presented as means ± SEM (WT chow n=3, SA chow n=3; **p<0.01 vs WT chow) (C)Glucose 
tolerance test excursion curve and (D) glucose tolerance test area under curve. Data are presented 
as means ± SEM (n=5/group; *p<0.05 vs WT chow). (E) Glucose tolerance test excursion curve 
and (F) glucose tolerance test area under curve. Data are presented as means ± SEM (n=5/group; 
*p<0.05, **p<0.01 vs WT chow) (G) Insulin tolerance test excursion curve and (H) insulin 
tolerance test area under curve. Data are presented as means ± SEM (n=5/group; **p<0.01 vs 
WT chow). (I) Pyruvate tolerance test excursion curve and (J) pyruvate tolerance test area under 
curve after 6 weeks of HFD. Data are presented as means ± SEM (WT-HFD n=5, SA-HFD n=9; 
*p<0.05, **p<0.01, ****p<0.0001 vs WT-HFD) 
 
Supplementary Figure 3. Six weeks of high-fat diet causes changes in glucose tolerance and 
body composition of both WT-HFD and SA-HFD mice. (A) Glucose  
2tolerance test excursion curve. Data are presented as means ± SEM (WT chow n=10,WT-HFD 
n=25, SA-HFD n=12; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 for WT chow vs. WT-
HFD; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001). (B)Glucose tolerance test area under 
curve. Data are presented as means ± SEM (WT chow n=10, WT-HFD n=25, SA-HFD n=12; 
***p<0.001 vs. WT-HFD. Changes in (C) total fat mass, (D) percent fat mass, (E) total lean 
mass and (F)percent lean mass after 6 weeks of chow diet or HFD were measured using 
EchoMRI. Data are presented as means ± SEM (WT-Chow n=10, WT-HFD n=20, SA-HFD 
n=12; **p<0.01, ****p<0.0001 vs WT-HFD). 
 
Supplementary Figure 4. Expression of genes related to mitochondrial metabolism, fatty 
acid oxidation and glucose metabolism in various tissues in SA-HFD mice. Gene expression 
analysis for Liver(A) Mitochondrial metabolism (B) Fatty acid oxidation (C) Glucose 
metabolism, TA (D) Mitochondrial metabolism (E) Fatty acid oxidation (F) Glucose metabolism, 
iBAT (G) Mitochondrial metabolism (H) Fatty acid oxidation (I) Glucose metabolism, ingWAT 
(J) Mitochondrial metabolism (K) Fatty acid oxidation (L) Glucose metabolism and small 
intestine (M) Mitochondrial metabolism (N) Fatty acid oxidation (O) Glucose metabolism. Data 
are presented as means ± SEM (n=5/group; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs 
WT-HFD) 
 
Supplementary Figure 5. Pair-feeding of WT mice (WT-HFD-PF) to SA-HFD mice over 6 
weeks of HFD (A) Schematic description of pair-feeding WT-HFD-PF mice the amount of food 
consumed by SA-HFD mice over 6 weeks of diet. (B)Daily food intake and (C) average food 
intake for all WT-HFD-PF mice was measured. (D) Changes in total fat mass and (E) total lean 
mass were measured using EchoMRI. Data are represented as Mean ± SEM (WT-HFD-PF n=9, 
SA-HFD n=10;**p<0.01 vs WT-HFD-PF)(F) Masson’s Trichrome staining of left atrial sections 
to indicate fibrosis (blue) levels relative to normal cardiac tissue (red) (Scale bar 200 μm) and 
(G) Percentage of fibrotic tissue normalized to WT. Data are presented as means ± SEM (SA-
HFD n=3; WT-HFD-PF n=5; *p<0.05). (H) Insulin tolerance and (I) area under curve for insulin 
tolerance was measured by injecting insulin1 unit per kg body weight i.p. Data are represented as 
Mean ± SEM (WT-HFD-PF n=9, SA-HFD n=10;**p<0.01 vs WT-HFD-PF). 
Supplementary Table 1: qPCR forward and reverse primer sequences for the genes 
measured, related to Supplemental Figure 4. 
Gene Forward Primer Sequence Reverse Primer Sequence 
Acsl1 ACACTTCCTTGAAGCGATGG GGCTCGACTGTATCTTGTGG 
Acsl3 GGCCAACGTGGAAAAGAAAG GTCTTGGAATCCTTCTCGCC 
Acsl4 GCACCTTCGACTCAGATCAC CCAGGTTTGTCTGAAGTGGG 
Acsl5 CGCCCCCATCTCCACTCCAG GCTTCAAACACCCAACATCCCATTGC 
Aldoa GCGACCACCATGTCTATCTG GAAAGTGACCCCAGTGACAG 
Cd36 TGGAGCTGTTATTGGTGCAG TGGGTTTTGCACATCAAAGA 
Cidea GGTGGACACAGAGGAGTTCTTTC CGAAGGTGACTCTGGCTATTCC 
Cpt1 AAAGATCAATCGGACCCTAGACA CAG CGA GTA GCG CAT AGT CA 
Cpt1a AAAGATCAATCGGACCCTAGACA CAG CGA GTA GCG CAT AGT CA 
Cs GACTACATCTGGAACACACTCAATTCA CGAGGGTCAGTCTTCCTCAGTAC 
Elovl3 GTGCTTTGCCATCTACACGGATG ATGAGTGGACGCTTACGCAGGA 
Eno1 CTTGCTTTGCAGCGATCCTA GAAGAGACCTTTTGCGGTGT 
Eno3 CTGTGCCTGCCTTTAATGTG CTTCCCATACTTGGCCTTGA 
Fabp3 AGAGTTCGACGAGGTGACAGCA TTGTCTCCTGCCCGTTCCACTT 
Fabp5 GACGACTGTGTTCTCTTGTAACC TGTTATCGTGCTCTCCTTCCCG 
Fatp1 TGCCACAGATCGGCGAGTTCTA AGTGGCTCCATCGTGTCCTCAT 
Fatp4 GACTTCTCCAGCCGTTTCCACA CAAAGGACAGGATGCGGCTATTG 
Fbp1 TGCTGAAGTCGTCCTACGCTAC TTCCGATGGACACAAGGCAGTC 
Ffar4 GTGACTTTGAACTTCCTGGTGCC CAGAGTATGCCAAGCTCAGCGT 
G6Pc AGGTCGTGGCTGGAGTCTTGTC GTAGCAGGTAGAATCCAAGCGC 
Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Glut4 ATCATCCGGAACCTGGAGG CGGTCAGGCGCTTTAGACTC 
Gpd1 CTCATCACGACCTGCTATGG CTGCTCAATGGACTTTCCAG 
Gpd2 GCGGACTCATCACAATAGCA TGAAGGAACAGCCCAACAG 
Gpi1 ATGGGCATATTCTGGTGGAC CCCGATTCTCGGTGTAGTTG 
Gyk CAAATGCAAGCAGGACGATG GGCCCCAGCTTTCATTAGG 
Hk2 AGAGAACAAGGGCGAGGAG GGAAGCGGACATCACAATC 
Idh3a GCAGGACTGATTGGAGGTCTTG GCCATGTCCTTGCCTGCAATGT 
Lipe TGGCACACCATTTTGACCTG TTGCGGTTAGAAGCCACATAG 
Lpl GATGCCCTACAAAGTGTTCCA AAATCTCGAAGGCCTGGTTG 
Mdh2 TCACTCCTGCTGAAGAACAGCC CCTTTGAGGCAATCTGGCAACTG 
Nrf1 CAACAGGGAAGAAACGGAAA GCACCACATTCTCCAAAGGT 
Nrf2 AGGTTGCCCACATTCCCAAACAAG TTGCTCCATGTCCTGCTCTATGCT 
Ogdh GGTGTCGTCAATCAGCCTGAGT ATCCAGCCAGTGCTTGATGTGC 
Pcx GGATGACCTCACAGCCAAGCAT GCAATCGAAGGCTGCGTACAGT 
Pdha1 GTGAGAACAACCGCTATGGCATG CGCAAACTTTGTTGCCTCTCGG 
Pfkl CCATCAGCAACAATGTGCCTGG TGAGGCTGACTGCTTGATGCGA 
Pfkm CTGGTGCTGAGGAATGAGAA TTCCTGTCAAAGGGAGTTGG 
Pfkp AAGCTATCGGTGTCCTGACC TCCCACCCACTTGCAGAAT 
Pgam1 GACGATCTTATGATGTCCCACC GTACCTGCGATCCTTGCTGA 
Pgam2 CTGCCTACCTGTGAAAGTCTC GACATCCCTTCCAGATGTTT 
Pgc1a GAATCAAGCCACTACAGACACCG CATCCCTCTTGAGCCTTTCGTG 
Pgc1b AGCCCGGAGTAT GCTCTGGTAGGGGCAGTGA 
Pgk1 GAGCCTCACTGTCCAAACTA CTTTAGCGCCTCCCAAGATA 
Pklr CGAAAAGCCAGTGATGTGGTGG GATGCCATCGCTCACTTCTAGG 
Pkm CTGTGGAGATGCTGAAGGAG CAACAGGACGGTAGAGAATGG 
Prdm16 ATCCACAGCACGGGTGAAGCCAT ACATCTGCCCACAGTCCTTGCA 
Tfam GTCCATAGGCACCGTATTGC CCCATGCTGGAAAAACACTT 
Tpi1 TATGGAGGTTCTGTGACTGGA CGGTGGGAGCAGTTACTAAA 
Ucp1 AGGCTTCCAGTACCATTAGGT CTGAGTGAGGCAAAGCTGATTT 
 
